Jennifer Hilton
Family · Paw Paw, MINPI 1598364770
Payments from drug & device makers
Across 347 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$742
- AstraZeneca$737
- AbbVie$380
- Boehringer Ingelheim$363
- Amgen$362
- Lilly USA, LLC$326
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,788100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $742 |
| AstraZeneca(2 entities) | 36 | $737 |
| AbbVie | 25 | $380 |
| Boehringer Ingelheim | 25 | $363 |
| Amgen | 18 | $362 |
| Lilly USA, LLC | 20 | $326 |
| Bayer | 12 | $276 |
| Johnson & Johnson | 26 | $252 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $248 |
| GSK | 11 | $227 |
| Axsome Therapeutics, Inc. | 4 | $176 |
| Pfizer | 9 | $166 |
| Mylan Specialty L.p. | 8 | $153 |
| Dexcom, Inc. | 9 | $144 |
| Teva Pharmaceuticals USA, Inc. | 8 | $137 |
| Merck | 6 | $92 |
| Amarin Pharma, Inc. | 5 | $90 |
| Jazz Pharmaceuticals Inc. | 5 | $86 |
| Novartis | 2 | $78 |
| Neurocrine Biosciences, Inc. | 4 | $77 |
| Biohaven Pharmaceuticals, Inc. | 4 | $75 |
| Philips North America LLC | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| Corcept Therapeutics | 4 | $51 |
| Nestle Healthcare Nutrition Inc. | 3 | $49 |
| Boston Scientific | 1 | $46 |
| Electromed, Inc. | 4 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Insmed, Inc. | 1 | $21 |
| Viiv Healthcare Company | 1 | $21 |
| Organon | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,802 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $86,116 |
| JardianceEmpagliflozin | 53 | $52,139 |
| MounjaroTirzepatide | 36 | $44,284 |
| EliquisApixaban | 42 | $40,439 |
| TrulicityDulaglutide | 29 | $40,432 |
| MyrbetriqMirabegron | 28 | $30,825 |
| FarxigaDapagliflozin Propanediol | 26 | $23,648 |
| XareltoRivaroxaban | 11 | $13,649 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,937 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,379 |
| Bupropion XlBupropion Hcl | 15 | $4,605 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,225 |
| Levothyroxine Sodium | 244 | $3,305 |
| Atorvastatin Calcium | 218 | $3,084 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $742 | $86,11669 claims |
| Lilly USA, LLCMounjaro, Trulicity | $326 | $84,71565 claims |
| Boehringer IngelheimJardiance | $363 | $52,13953 claims |
| PfizerEliquis | $166 | $40,43942 claims |
| AstraZenecaFarxiga, Symbicort | $737 | $27,87342 claims |
| Johnson & JohnsonXarelto | $252 | $13,64911 claims |
| GSKArnuity Ellipta | $227 | $5,93723 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $35 | $5,37912 claims |
| AbbVieSynthroid | $380 | $90511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Paw Paw
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.